A Phase 3 interventional study of Ritlecitinib and Ritlecitinib 100 mg in Vitiligo, sponsored by Pfizer. Active, not recruiting at 73 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.
Among the 80 studies in Vitiligo with a site in United States, this one is the 7th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2024, is one of 12 in phase 3, reaches primary completion later than 9 of the 23 other live ones, and was the 67th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Poland
Ages 18–65
CorEvitas · Sites in United States
Ages 12+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–99
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Sites in United States, Taiwan
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 14 · Phase 4 1
First in 1995; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 37 across the 68 interventional studies, 1,750 across the 12 observational. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 80 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Vitiligo — fewer than ten, so there is no comparison to draw.
8 of the studies in Vitiligo with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163326Phase 3PfizerA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | 2027-03-31 |
| NCT06072183Phase 3PfizerA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | 2027-07-30 |
| NCT03577327Northwestern UniversityThe Gut and Skin Microbiome in Vitiligo Disease Progression | 2026-12 |
| NCT07223229Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | 2026-12-31 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Vitiligo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).
Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.
Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:
This study is seeking for participants who:
All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home.
Participants may receive the study medicine or placebo for up to 52 weeks.
The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo.
Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study.
Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040. Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned.
Drug: Ritlecitinib · Drug: Ritlecitinib 100 mg · Drug: Placebo
Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned
Drug: Ritlecitinib · Drug: Ritlecitinib 100 mg · Drug: Placebo
Ritlecitinib 50 mg capsule once daily
Ritlecitinib 100 mg capsule once daily
Matching capsule once daily
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation
To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo
Time frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
Incidence of clinically significant laboratory abnormalities
To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo
Time frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
Response based on T-VASI75 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 75% improvement in T-VASI from Baseline
Time frame: Baseline to week 52
Response based on F-VASI75 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline
Time frame: Baseline to week 52
Response based on T-VASI50 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 50% improvement in T-VASI from Baseline
Time frame: Baseline to Week 52
Response based on F-VASI50 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 50% improvement in F-VASI from Baseline
Time frame: Baseline to week 52
Response based on T-VASI90 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 90% improvement in T-VASI from Baseline
Time frame: Baseline to week 52
Response based on F-VASI90 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 90% improvement in F-VASI from Baseline
Time frame: Baseline to week 52
Response based on T-VASI100 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 100% improvement in T-VASI from Baseline
Time frame: Baseline to week 52
Response based on F-VASI100 at weeks 4, 8, 12, 24, 36 and 52
Proportion of participants achieving at least a 100% improvement in F-VASI from Baseline
Time frame: Baseline to week 52
Patient Global Impression of Severity-Face (PGIS-F) at weeks 24, 36, and 52
To assess the effect of ritlecitinib compared to placebo on the PGIC-F at weeks 24, 36, and 52
Time frame: Baseline to week 52
Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) at weeks 24, 36, and 52
To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Week 24, 36, and 52
Time frame: Baseline to week 52
Patient Global Impression of Change-Face (PGIC-F) at week 24, 36, and 52
To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Week 24, 36, and 52
Time frame: Baseline to week 52
Patient Global Impression of Change- Overall vitiligo (PGIC-V) at weeks 24, 36, and 52
To assess the effect of ritlecitinib compared to placebo on the PGIC-V at weeks 24, 36, and 52
Time frame: Baseline to week 52
Proportion of participants achieving disease stabilization
The difference in the proportion of participants with stable disease at all scheduled timepoints
Time frame: Baseline to week 52
Percentage change from baseline (%CFB) in F-VASI at weeks 4, 8, 12, 24, 36, and 52
To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo
Time frame: Baseline to week 52
Percentage change from baseline (%CFB) in T-VASI at weeks 4, 8, 12, 24, 36, and 52
To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo
Time frame: Baseline to week 52
Time to loss of response (<F-VASI75 and <T-VASI50 at the same visit).
To compare the efficacy of ritlecitinib 100 mg QD, 50 mg QD, and placebo
Time frame: Baseline to week 52
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 38 months after the start.
Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 38 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600